

Original Research Article

Isolation, Identification and Speciation of Candida Species from Various Clinical Specimens in a Tertiary Care Hospital in Chennai

Dr. A. Arasi Samyuktha¹, Dr. Chitrlekha Saikumar²

Department of Microbiology, Sree Balaji Medical College and Hospital, Chrompet, Chennai, Tamilnadu, India

***Corresponding author**

Dr. A. Arasi Samyuktha

Email: samyuktha.arasi15@gmail.com

Abstract: The aim and objective of the study was to isolate Candida species, find its frequency from various clinical samples (sputum, urine, high vaginal swab, ET tube swab, nail clippings, pus, etc.), their speciation and to bring out the various risk factors associated with candidiasis. A total of 250 Candida species isolated from various clinical specimens in our institute from June 2016 to June 2017 were included in the study. Standard yeast identification protocol and Hichrom agar were used for speciation. Out of the total 2350 clinical samples, 250 candida species were isolated, thus the prevalence of 9.4%. Among the 250 culture positive cases, 118 (47.2%) *C. albicans*, 64 (25.6%) *C. tropicalis*, 75 (30%), *C. glabrata*, 38 (15.2%), *C. krusei* 14 (5.6%) and *C. parapsilosis* 5 (2%) were obtained. Non albicans Candida predominated (52.8%) over *Candida albicans* (47.2%). Males were affected more than the females. In both the sexes maximum patients belonged to the age group of >60 years. In the present study prevalence of candidiasis is 9.4%. The risk factors for candidiasis noted in this study were diabetes mellitus, prolonged antibiotic therapy, steroids and pregnancy. Along with *Candida albicans*, non-albicans *Candida* (NAC) species like *C. glabrata*, *C. krusei*, *C. tropicalis* and *C. parapsilosis* are increasingly being isolated from clinical samples. Characterization upto species level is important for early treatment decisions and effective management as some NAC species are intrinsically resistant to antifungal agents. Hichrom *Candida* agar is useful for the primary isolation and differentiation of medically important *Candida* species.

Keywords: *Candida*, Speciation, Hichrom agar, non-albicans *Candida*

INTRODUCTION:

Candida is one of the most commonly encountered opportunistic fungi that cause superficial mucosal infections usually, but can invade tissue and produce life threatening pathology caused by alteration of immune defenses. There are various conditions in which the normal equilibrium between *Candida* and the host is altered and it leads to pathologic state: extremes of age, pregnancy, diabetes, prolonged administration of antibiotics secondary to bacterial infections, steroid therapy and AIDS [1]. Species level identification of *Candida* is important as Non albicans *Candida* (NAC) species have replaced *Candida albicans* as the predominant pathogen and are more resistant to antifungal drugs. Speciation of *Candida* can be done using Hichrom agar, which is a differential culture medium and facilitates the isolation and identification of some clinically important *Candida* species.

Candidiasis refers to infection caused by any of the species of the genus *Candida*. Incidence of *Candidiasis* is increasing worldwide. Two major medical events have revived the interest in fungal diseases in general and *Candida* infections in particular. The first was the introduction of antibacterial drugs in the second half of the twentieth century. These drugs may act as a predisposing factor for mycotic infections causing an imbalance of host's natural microbial flora in favour of fungi, upon which they have inhibitory activity. The second event was the increase in the prevalence of immunosuppressed patients during the last few decades, as a result of chemotherapy or disease [AIDS], which led to a parallel increase in the incidence of *Candida* infections in general and non-albicans *Candida* species in particular [2]. The shift of *Candida* species from

commensal to potent pathogen is facilitated by a number of virulence factors such as adherence to host tissues and medical devices, biofilm formation and secretion of extracellular hydrolytic enzymes[3].

Candida albicans accounts for 40-60% yeasts isolated in developed countries, whereas Indian reports show an increased predominance of non *albicans* *Candida* spp. The emergence of non-*albicans* *Candida* spp. may represent selection of less susceptible species like *C. glabrata* and *C. Krusei*. *C.glabrata* is less susceptible and *Candida krusei* is intrinsically resistant to Fluconazole. *C. tropicalis* has the highest adherence rate to inanimate materials such as urinary and vascular catheters, and is often involved in biofilm formation, that is more resistant to Antifungal agents. Resistance to Azoles in *C. tropicalis* and *C. albicans* has also been increasingly reported [4-6]. Identification of *Candida* to species level is definitely warranted as there is increase in the incidence of non-*Candida albicans* infections [7].

Since molecular techniques are very expensive, usage of CHROM agar for species identification would be of benefit for easy and rapid speciation [8]. These rapid speciation methods can also provide information on the susceptibility to Fluconazole and hence aid in early treatment decisions.

MATERIALS AND METHODS:

A prospective study was undertaken at our institute for a period of 1 year from JUNE 2016 to june

2017. Specimens were collected from OPD/IPD of Sree Balaji medical college and hospital, Chrompet ,Chennai.Out of the total 2350 samples received in the central laborartory , 250 *Candida* species isolated from various clinical specimens like urine,sputum,high vaginal swab, pus etc.were included in the study.Gram stain was performed from direct samples and inoculated on sabourads dextrose agar at 37°C for 24 hours. The plates were read at 24 and 48 hrs after incubation.

White to cream-colored, pasty and smooth colonies appeared in within 24 hours to 48 hrs.[Fig 2,3] These colonies morphologically resembling the members of genus *candida* were subjected to gram staining. On microscopic examination they appeared as gram-positive budding yeast cells with or without pseudohyphae (Fig 4). Germ tube test was done and the positives were identified as either *C.albicans* or *C.dubliniensis*.*C.albicans* was further identified by growth at 45°C and chlamydospore formation on corn meal agar. All the isolates were subjected to sugar fermentation and sugar assimilation tests for final confirmation of the species.Simultaneously the *Candida* spp. were inoculated on Hichrom *Candida* agar and incubated at 37°C for 24 hrs and the species were identified by type and colour of the colonies on Hichrom *Candida* agar as per manufacturer’s instructions[TABLE 1, Fig 5, 6,7,]. Hichrom *Candida* agar is a novel, differential culture medium that is claimed to facilitate the isolation by colorimetric presumptive identification [9,10].

Table-1: appearance of candida species on hichrom candida agar

S.No	Candida species	Colony colour of Candida species
1	<i>C. albicans</i>	Light green
2	<i>C. krusei</i>	Pink
3	<i>C. parapsilosis</i>	White
4	<i>C. tropicalis</i>	Dark blue
5	<i>C. glabrata</i>	Cream coloured

RESULTS:

250 clinical isolates of *candida* species confirmed by standard yeast identification protocols were included in the study and the prevalence of Candidiasis was 9.4% in various clinical specimens. Non-*albicans* *candida* (52.8%) isolates was more than *Candida albicans* (47.2%)[table 2]. Among non-*albicans* species, *C. tropicalis* was 30% followed by *C. glabrata* 15.2% , *C. krusei* 5.6% and *C. parapsilosis* 2% were the major isolates.[table 3] Males (51.2%) predominated over females (48.8%) patients.[table 4] Males were affected more than

females. Maximum number of *Candida* isolates were from the age group >60 years[table 5]. Maximum number of *Candida* isolates was from urine, followed by sputum, high vaginal swab and pus .Split up of the *Candida* isolates is shown in [Fig.1]. *Candida albicans* was the major isolate from sputum. *Candida tropicalis*, *Candida glabrata* & *Candida krusei* was the major isolates from urine. Maximum *Candida* isolates were from medicine followed by nephrology, urology, surgery, ICU,ENT ,paediatrics ,chest and TB, gynaecology & dermatology[table 6]. Diabetes mellitus was the most commonly associated risk factor,

followed by the use of broad-spectrum antibiotics and indwelling Foleys catheter. Pregnancy and the use of

steroids were the other risk factors recorded by our study [table 7]

Table-2: Distribution of candida albicans and non albicans candida isolates

CANDIDA SPECIES	NUMBER OF ISOLATES	PERCENTAGE(%)
CANDIDA ALBICANS	118	47.2%
NON ALBICANS CANDIDA	132	52.8%
TOTAL	250	100%

Table-3: Distribution of candida species in clinical specimens

CANDIDA SPECIES	TOTAL	PERCENT(%)
Candida albicans	118	47.2%
Candida tropicalis	75	30%
Candida glabrata	38	15.2%
Candida krusei	14	5.6%
Candida parapsilosis	5	2%
TOTAL	250	100%

Table-4: Gender distribution of the study population

GENDER	NUMBER	PERCENT(%)
MALE	128	51.2
FEMALE	122	48.8
TOTAL	250	100

Table-5: Age distribution of the study population

AGE(years)	NUMBER OF CASES	PERCENT(%)
0-10	13	5.2
11-20	4	5.6
21-30	5	2
31-40	31	12.4
41-50	33	13.2
51-60	71	28.4
>60	93	37.2
TOTAL	250	100

Table-6: Wardwise distribution of the study population

WARD	NUMBER OF PATIENTS
MEDICINE	50
NEPHROLOGY	40
UROLOGY	30
GYNAECOLOGY	28
ICU	26
SURGERY	22
DERMATOLOGY	20
CHEST AND TB	18
PAEDIATRICS	16
TOTAL	250

Table-7: Associated risk factors for candidiasis

Risk factors	Number= n/250	Percentage
Diabetes mellitus	94	37.6%
Broad spectrum antibiotics	42	16.8%
Urinary catheterization	36	14.4%
Pregnancy	32	12.8%
Steroids	46	18.4%




Fig-1: Distribution of Candida Species among Various Samples



Fig-2: growth in SDA



Fig-3: Dry wrinkled colonies of non-albicans candida in SDA




Fig-4: Gram positive budding yeast cells in gram stain



Fig-5: Pink colour colonies of candida krusei in hichrom agar



Fig-6: Blue colour colonies of *c. tropicalis* in chrom agar



Fig-7: light green colour colonies of *c. albicans* in chrom agar

DISCUSSION:

The incidence of yeast infection has increased in the last two decades. Incidence and prevalence of all forms of Candidal infections has risen abruptly. In the present study, prevalence of candidiasis was 9.4%

in various clinical specimens. NAC (52.8%) was isolated at higher rates than *Candida albicans* (47.2%) which correlates with reports by other workers. Vijaya D *et al* [9] showed 46% *C. albicans* isolates, Grace *et al* [11] showed 43.15% *C. albicans*, Prasad *et*

al. showed 47.6% [12] *C. albicans*. and Sachin C. Deorukhkar *et al* [13] showed 39.2% *C. albicans*.

In our study most common species isolated was *C. albicans* 47.2%. The predominant NCA isolated in our centre was *C. tropicalis* 30%, which was similar in studies done by Ragini *et al.*, [14] Vijaya *et al.*, [9] and Saroj *et al.* Other non-*albicans* candida species isolated were *C. glabrata* 15.2%, *C. krusei* 5.6% and *C. parapsilosis* 2%. Similar observation was documented by Dasari Sarada *et al* [15]., Sachin C. Deorukhkar *et al.* [13] and C A Kauffman *et al.* [16] In the study by Sachin C. Deorukhkar *et al.* [13] out of 523 *Candida* spp. isolated from various clinical specimens, 192 (36.7%) were *C. albicans* and 331 (63.3%) were NAC spp. Among the NAC spp., *C. tropicalis* (35.1%) followed by *C. glabrata* (28.1%) and *C. krusei* (16.3%) was the major isolates, which is comparable with our study.

In our study majority of candida spp. was isolated from urine 41.6%, followed by sputum 20.4%, high vaginal swab 14% and pus 6%. Of these >50 % of urinary candida isolates belongs to NAC spp. Our observation is similar to that of F Alvarez-Lerma *et al.* [17] and C A Kauffmann *et al.* [16], where >50% of urinary *Candida* isolates belonged to NAC spp.

In the present study, most of the candida isolates was found to be higher in male patients 128(51.2%) as compared to female patients 122 (48.8%) with male to female ratio of 1:0.95. This [12] correlates well with from R A Kashid *et al* [14] who reported the isolation of *Candida* species was higher in males 81 (55.10%) as compared to females 66 (44.8%) with male to female ratio of 1:0.81. Our study differed from Amar C S *et al.* who isolated *Candida* species more from female 62 (60.2%) than male 41 (39.8%) patients in ratio of (M: F) 0.66:1 [18].

We observed that the frequent isolation of *Candida* species was in the age group above 60 years (37.2%) which was similar with the study of R A Kashid *et al* [14]. who reported highest incidence in the age group above 60 years (24.48%). In a study done by Aikaterini Flevari *et al* [19] it is said that *Candida* species remain the most important cause of opportunistic infections worldwide, affecting predominantly patients over 65 years of age.

The potential clinical importance of species-level identification of *Candida* species lies in the fact

that they differ in the expression of virulence factors and antifungal susceptibility. For differentiation between different species of candida conventionally Germ tube test, chlamyospore formation, sugar fermentation and assimilation tests are being used which are laborious and time consuming. Hichrom agar is a rapid method to differentiate between different candida species. It facilitates identification of candida species in 24-48 hours. As per our study, Hichrome agar was found to have the advantage of being technically simple and rapid and cost effective as compared to the conventional methods In the present study, Hichrome agar *Candida* identified all *Candida albicans*, *C. tropicalis*, *C. glabrata*, *C. krusei* and *Candida parapsilosis* which correctly correlates with study by Willinger B [20] *et al* [22], Momani OM *et al* [21] and Gultekin *et al* [22].

CONCLUSION:

This study emphasizes the requirement of rapid and precise identification of *Candida* isolates upto species level. Prevalence of candidiasis is 9.4% in various clinical samples and non *albicans* candida predominated *Candida albicans*. There is an increase in the prevalence of non- *albicans* candida. Prevalence of candidiasis was found to be higher in patients associated with predisposing factors like indwelling vascular catheters, prolonged antibiotic therapy and diabetes mellitus. The advantages of Hichrom candida agar is that it provides for the rapid isolation and identification of medically important candida species in a resource-limited setting and it potentially decreases the laboratory cost which is required for effective management strategies. Effective treatment requires both early diagnosis and prompt initiation of therapy against fungal infection thus decreasing patients' morbidity and mortality.

REFERENCES:

1. Rippon J W, Candidiasis and the Pathogenic Yeasts. In Medical Mycology, 3rd (eds) Philadelphia : WB Saunders, 1998;536-81.
2. Topley Wilson's Microbiology and Microbial infections , Medical Mycology, 10th edition, 2005, Chapter-30, Candidiasis , Pg :579-620.
3. Sardi J. C. O., Scorzoni L., Bernardi T., Fusco-Almeida A. M.,
4. Mendes Giannini M. J. S. *Candida* species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. Journal of Medical Microbiology, 2013;62(1):10-24.

5. Pfaller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ. Trends in antifungal susceptibility of *Candida spp.* isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. *J Clin Microbiol* 2002;40:852-6.
6. Chakrabarti A, Mohan B, Shrivastava SK, Marak RS, Ghosh A, Ray P. Change in distribution and antifungal susceptibility of *Candida* species isolated from Candidaemia cases in a Tertiary care centre during 1996-2000. *Indian J Med Res* 2002; 116 :5-12.
7. Xisto Sena Passos, Werther Souza Sales, Patrícia Jackeline Maciel, Carolina Rodrigues Costa, Karla Carvalho Miranda, Janine de Aquino Lemos, *Candida* colonization in intensive care unit patients' urine; Rio de Janeiro, Vol. 100(8): 925-928, December 2005.
8. Golia S, Reddy K M, Karjigi K S, and Hittinahalli V. Speciation of *Candida* using chromogenic and cornmeal agar with determination of fluconazole sensitivity. *Al Ameen J Med Sci* 2013; 6 (2): 163-166.
9. Kashid R A, Belawadii S, Devi G, Indumati. Characterization and antifungal susceptibility testing for candida species in a tertiary care hospital. *Journal of Health Sciences and Research*. August 2011; 2 (2): 1-7.
10. Vijaya D., HarsHa T.r., NagaraTNamma T., *Candida* Speciation Using Chrom Agar The *Journal of Clinical and Diagnostic Research*. 2011 August. Vol-5(4): 755-758
11. Paritpokee SI, Hall GE, Procop GA. Rapid identification of yeast isolates using BD BBL™ CHROMagar™ *Candida*. In 105th General Meeting of the American Society for Microbiology 2005.
12. Grace L, Tan, Ellena M Peterson. CHROM agar candida medium for direct susceptibility testing of yeast from blood culture . *J Clin Microbiol* 2005;43:4:1727-1731.
13. Prasad KN, Agarwal J, Dixit AK, Tiwari DP. Role of yeasts as nosocomial pathogens & their susceptibility to fluconazole & amphotericin B. *Indian Journal of Medical Research*. 1999 Jul 1;110:11.
14. Deorukhkar SC, Saini S, Mathew S. Non-albicans *Candida* infection: an emerging threat. *Interdisciplinary perspectives on infectious diseases*. 2014 Oct 22;2014.
15. Kashid RA, Belawadi S, Devi G, Dadich D. Characterization and antifungal susceptibility testing for *Candida* species in a tertiary care hospital. *J. Health Sci. Res*. 2011 Aug;2(2):1-7.
16. Sarada D, Giddi S, Reddy M, Sisira D. Isolation and speciation of candida from clinical samples in a tertiary care hospital at Kurnool, Andhra Pradesh, India. *Journal of Evolution of Medical and Dental Sciences*. 2014 Dec 25;3(73):15431-7.
17. Kauffman CA. Candiduria. *Clinical Infectious Diseases*. 2005 Sep 15;41(Supplement_6):S371-6.
18. Álvarez-Lerma F, Nolla-Salas J, León C, Palomar M, Jordá R, Carrasco N, Bobillo F. Candiduria in critically ill patients admitted to intensive care medical units. *Intensive care medicine*. 2003 Jul 1;29(7):1069-76.
19. Amar CS, Ashish J, Hajare V, Belagali Y. Study of prevalence and antifungal susceptibility of candida. *International Journal of Pharma and Bio Sciences*. 2013;4(2):361-81.
20. Flevari A, Theodorakopoulou M, Velegraki A, Armaganidis A, Dimopoulos G. Treatment of invasive candidiasis in the elderly: a review. *Clinical interventions in aging*. 2013;8:1199.
21. Willinger B, Manafi M. Evaluation of CHROMagar *Candida* for rapid screening of clinical specimens for *Candida* species. *Mycoses*. 1999 Jan 1;42(1-2):61-5.
22. Om M. Cost effectiveness and efficacy of Chrom agar candida medium in clinical specimen. *East Mediterr Health J*. 2000;6(5-6).
23. Gültekin B, Yazici V, Aydin N. Distribution of *Candida* species in vaginal specimens and evaluation of CHROMagar *Candida* medium. *Mikrobiyoloji bulteni*. 2005 Jul;39(3):319-24.